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The annual congress of the Heart Rhythm Society (HRS) 
held earlier this year in San Francisco drew attendees 
from around the world, confirming the high value of 
the conference and the prominent role of the congress in 
the international cardiac electrophysiology community. 
Upon browsing the program, it appeared that there was 
a resurgent interest in gaining a better understanding of 
the different potential mechanisms underlying both par-
oxysmal and persistent atrial fibrillation (AF) and which 
ablation strategies should be chosen to achieve an effec-
tive outcome.
Besides this, an overwhelming amount of data were pre-
sented on the subject of novel ablative approaches for 
both AF and ventricular tachycardia (VT), thus heralding 
an expected future improvement also in the treatment of 
the most complex cardiac arrhythmias.
In this commentary, I would like to emphasize certain 
aspects related to the newest ablative techniques and 
address particular topics in the field of cardiac pacing 
and upcoming new modalities of remote cardiac rhythm 
monitoring as indicators of the rapid evolution ongoing 
in telemedicine.
New concepts in the treatment of atrial 
 fibrillation
Persistent AF is understood by far to be the most chal-
lenging atrial arrhythmia to be treated by ablation. In the 
electrophysiology community, there is a clear consensus 
that the achievement of pulmonary vein (PV) isolation 
(PVI) is not adequate enough to treat patients suffering 
from persistent AF. In this regard, the location of so-called 
“non-PV triggers” is considered of pivotal significance in 
order to improve the success rate of ablation. To this end, 
Dr. Francis Marchlinski offered a significant contribution 
to the understanding of the role of non-PV triggers with 
his presentation, which highlighted the concept that, 
if PVs are isolated and there is still AF, there therefore 
must be non-PV triggers located elsewhere in the atria.1 
He defined the protocols for initiating non-PV triggers, 
ranging from an infusion of incremental doses of isopro-
terenol up to 30 mcg/min to the use of burst pacing dur-
ing isoproterenol infusion and adenosine administration. 
Prior research suggests that non-PV triggers are more 
frequently induced in females and more often found in 
the left atrium (> 70% of cases) than in the right atrium, 
with site locations including the crista terminalis (CT), 
the coronary sinus, in the antra of PVs, and the left atrial 
appendage (LAA).2,3 One understood clue for unmask-
ing triggers is to position multipolar catheters in different 
locations such as along the CT, LAA, and in the coronary 
sinus. Most important is the validation of the value of 
The Journal of Innovations in Cardiac Rhythm Management, August 2019 3796
non-PV trigger elimination by repeating the provocation 
protocol. This approach, by ensuring the elimination of 
non-PV triggers, can significantly improve the clinical 
outcome as compared with in patients in whom non-PV 
triggers are not eliminated during the redo procedure. Dr. 
Marchlinski alluded to this in his presentation, stressing 
that the occurrence of non-PV triggers at the repeat pro-
cedure identifies a poorer outcome.
Another extensively discussed topic was LAA electri-
cal isolation in patients with long-lasting persistent AF, 
covered by Dr. Luigi Di Biase.4 This remains a hot topic 
in electrophysiology, since it appears that secondary 
foci can be identified in the LAA in about 20% to 25% 
of patients with persistent AF,5 and prior clinical data 
suggest that the procedural outcome is better when the 
LAA is electrically isolated even during the index pro-
cedure.5 The rationale supporting LAA isolation relies 
on the thought that the prevalence of non-PV triggers 
(and therefore also the likelihood of the LAA being a 
source of secondary triggers) is higher in patients with 
long-lasting persistent AF. Furthermore, the LAA hosts 
cells with automaticity, which can remain active even 
after extensive atrial substrate ablation and PVI, lead-
ing to a greater chance for arrhythmia recurrence. Clin-
ical data from different groups have demonstrated the 
reproducibility of LAA isolation, providing evidence 
that this approach can play a role in improving the 
clinical outcome of patients with persistent AF. In this 
regard, a recent meta-analysis by Romero et al.6 corrob-
orated the suggestion that LAA isolation constitutes a 
clinical benefit when included in the ablative strategy 
for patients with persistent AF.
The safety of catheter ablation of AF remains of pivotal 
importance and was discussed by Dr. David Haines, 
who also pointed out the subtle risk of promoting micro-
emboli during radiofrequency (RF) delivery in the left 
atrium.7 In his presentation, Dr. Haines explored the 
subject in question, underlying the main biophysical 
aspects of RF current and stressing that it is important 
to pay full attention to anticoagulation, sheath manage-
ment, and the unique features of the ablation techno-
logy being employed in each case. Probably the most 
striking results that Dr. Haines presented were related 
to the potential neuropsychological effects and the sub-
tle cognitive dysfunction that can be detected after AF 
ablation. Specifically, reduced brain dysfunction, as 
demonstrated with brain magnetic resonance imaging, 
is more pronounced in the first six months after abla-
tion, but progressively lessens over time.8 Again, the 
main cause of this finding was the promotion of micro-
emboli formation during RF delivery, which favors the 
occurrence of asymptomatic cerebral lesions. In order 
to minimize the occurrence of asymptomatic cerebral 
emboli, Dr. Haines suggested that he supports the 
exploration of a multifaceted protocol that includes a 
proper transseptal technique, sheath flushing, optimal 
anticoagulation, avoidance of overpowered ablation, 
and possibly the use of improved ablation algorithms 
and catheter designs.
News from the late-breaking clinical trials
As always, the late-breaking clinical trials sessions are 
ripe with intriguing data. From among them, for this 
commentary, I sought to focus on the potential role of 
vagus nerve stimulation to suppress AF, which has been 
extensively investigated in the last few decades and 
which remains a controversial topic. During one session, 
Dr. Stavros Stavrakis offered up the latest results of the 
Transcutaneous Electrical Vagus Nerve Stimulation to 
Suppress Atrial Fibrillation (TREAT-AF) randomized 
clinical trial, where 53 patients with paroxysmal AF were 
subdivided into two arms: an active group receiving 
vagus nerve stimulation at the tragus and a sham group 
receiving earlobe stimulation.9 The study in question 
demonstrated that, after combining the results recorded 
at the three- and six-month follow-up points, the median 
AF burden was reduced by 75% in the active group as 
compared with in the sham group. These impressive 
clinical results support the validity of pursuing further 
exploration of noninvasive neuromodulation to treat AF.
In the scenario of catheter ablation, one of the main 
challenges is by far the successful ablation of ventricu-
lar arrhythmias, including—in particular—so-called 
intractable VT and premature ventricular contractions 
(PVCs). In this regard, specific interest has grown regard-
ing the use of intramural infusion needle to ablate deep 
localizations of ventricular rhythms. Dr. Tomofumi Naka-
mura presented preliminary data on the application of 
this technique in 19 patients with PVCs/VTs with deep 
origins in the septum or left ventricular summit.10 All of 
these patients had undergone a previous failed ablation 
attempt, and the infusion needle ultimately produced 
acute arrhythmia elimination in 68% of patients, with the 
arrhythmia burden reduced from 24.2% ± 8.5% to 2.7% ± 
5.4% and the left ventricular ejection fraction improved 
from 32.4% ± 11.4% to 42.4% ± 6.8%, respectively. These 
preliminary clinical data suggest the technique presented 
is a promising ablative therapy for the management of 
intramural ventricular arrhythmias that have failed 
standard catheter ablation.
The search for an effective energy source to achieve dura-
ble lesions in AF ablation has been an attractive goal for 
several investigators in the last few decades, and the time 
for the availability of an alternative energy option to RF 
current has come. Pulsed electric-field ablation (PFA) 
has been investigated for a number of years to date and 
now finally seems ready to be employed in the clinical 
setting. The technology promotes cell death through the 
nonthermal mechanism of irreversible electroporation. 
During a late-breaking clinical session at HRS 2019, Dr. 
Jacob Koruth discussed the preliminary data for endocar-
dial mono- or biphasic PFA for PVI in a swine model.11 
The study demonstrated comparable chronic PVI rates 
for the two PFA waveforms, but biphasic PFA did not 
require neuromuscular paralysis as was necessary with 
the monophasic approach, and this constitutes a basis 
for possible clinical use of the biphasic PFA waveform 
in humans. Furthermore, since myocardial cells are 
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particularly sensitive to PFA as opposed to other organs 
like the esophagus, larger vessels, and nerves, the use of 
this disruptive technology seems to be highly promising 
for specific deployment in humans, since potential com-
plications are expected to be limited.
Cryoenergy has become an established effective alterna-
tive energy source for the ablation of AF, in part because 
it is less likely to adversely impact areas surrounding the 
target (i.e., cooling effect is more reversible) and may be 
less painful than RF ablation. To this end, data on the 
use of an ultra-low-temperature cryoablation system 
were presented by Dr. Felix Bourier, who discussed the 
safety, efficacy, and long-term durability results of using 
a preshaped catheter to deliver ultra-low cryoenergy in a 
porcine model.12 This technique reportedly led to effec-
tive lesion formation both in the atria and in the ven-
tricles as demonstrated by extensive three-dimensional 
mapping and histopathology. More striking was the 
finding that the lesions were confirmed even at a 90-day 
reevaluation point in animals that underwent three-di-
mensional remapping and histopathology. No major 
complications occurred. The study authors concluded 
that this novel modality of cryoenergy application might 
be safely deployed in humans to attain a higher degree of 
lesion durability.
New avenues in cardiac pacing
His-bundle pacing has been a hot topic in the last few 
years and, during HRS 2019, there were several presenta-
tions on the subject. Of note, a poster by Zanon et al.13 
suggested reducing the minimum value of the pacing 
threshold along with performing a simultaneous optimi-
zation of the sensing capability of the apical back-up lead. 
This approach ultimately led to an energy consumption 
savings of 24%, thus increasing the device longevity by 
32%. To counteract potential skepticism about the role 
of His-bundle pacing, another poster14 discussed a long-
term follow-up (more than five years) of more than 400 
patients, finding effective, persistent His-bundle pacing 
was successful in 81% of them and a requirement for rein-
tervention in the same time period only occurred in 5.5%.
Also in the field of pacing, the talk given by Dr. Petr  Neuzil 
about the current status of leadless implantable cardio-
verter-defibrillator (ICD) and cardiac resynchronization 
therapy (CRT) technology was of great interest.15 With the 
advent of the leadless pacemaker, a future goal has evolved 
into being, which is to devise a technology able to provide 
both effective ICD intervention and a CRT effect. Dr. Neuzil 
discussed the latest results obtained from a recent study in 
this area,16 which demonstrated a degree of feasibility for 
establishing a reliable communication between a current 
leadless pacemaker and an extravascular ICD, offering the 
capability for not only effective shock delivery/antitachy-
cardia pacing but also accurate monitoring of the cardiac 
rhythm after a shock is delivered. Additionally, efforts are 
still ongoing to actualize a full leadless ICD/CRT device: 
this is the focus of the Wireless Stimulation Endocardi-
ally for CRT (WiSE-CRT) study,17 which includes different 
components: a coimplanted leadless right ventricular 
pacemaker; a receiver electrode implanted in the left endo-
cardium; a battery implanted subcutaneously in the left 
mid-axillary line, and a phased ultrasound transmitter 
implanted submuscularly using cardiac echocardiogra-
phy. Briefly, the system, via the submuscular transmitter, 
provides synchronization with the right ventricular pacing 
pulse to transmit ultrasound energy to the left endocardial 
receiver to provide biventricular pacing. The aim with this 
device was to avoid the use of any intravascular compo-
nents so as to reduce complications such as infections, lead 
malfunction, and issues with surgically created pockets 
that currently still constitute major confounding factors in 
the management of intravascular devices.
Remote arrhythmia detection: state-of-the-art 
and future opportunities
Last but not least, the subject of adopting novel wearable 
devices for detecting cardiac arrhythmia disorders includ-
ing specifically AF was one of focus.18 This interest is 
related to the continued desire to address the overwhelm-
ing burden that cardiac disorders can produce through the 
introduction of newer and more innovative technologies. 
In this regard, providers must understand key concepts 
in electrophysiology science and management, includ-
ing the effectiveness and complications of the diagnosis 
and how to manage patients appropriately. Therefore, the 
advent of new diagnostic tools such as wearable devices 
and watches are crucial to encourage an open discussion 
of guidelines, perceived challenges, and future directions 
in clinical practice to optimize patient care. The different 
symposia on this hot topic were well-designed for the 
physicians and allied health care providers alike who 
are in charge of managing arrhythmic patients who are 
also at risk of comorbidities. Remote diagnosis of cardiac 
arrhythmia disorders and better communication among 
patients, physicians, and other health care providers will 
become more crucial in the years to come and will be an 
important step in improving patient care.
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